Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,528.52
(
2.91%
)
US TECH 100
23,134.00
(
3.59%
)
Dow Jones
46,341.51
(
2.49%
)
Brent Oil
103.14
(
-5.00%
)
Bitcoin
68,042.86
(
2.01%
)
News Focus
News Focus
Post# of 257323
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122830
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 196831

Friday, 11/13/2015 1:18:02 PM

Friday, November 13, 2015 1:18:02 PM

Post# of 257323
(AGN)—Auven Therapeutics (private) reports phase-2b/3 data in dry-eye disease:

http://finance.yahoo.com/news/auven-therapeutics-announces-positive-results-123000810.html

Auven’s drug candidate, Seciera, is a proprietary formulation of cyclosporine, which is the active ingredient in AGN’s second-biggest-selling drug, Restasis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today